Genetic Mutations as Risk Predictors of Atrial Fibrillation Recurrence After Catheter Ablation?

Journal of the American College of Cardiology

Volumn 55, Issue 8, 2010, Pages 754-757

  Hall, Jennifer L ^a   Barac, Ana ^b   Benjamin, Emelia J ^c,d  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FRAMINGHAM HEART STUDY   (United States)

Author keywords

atrial fibrillation; catheter ablation; gene variants

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN;

CATHETER ABLATION; CHROMOSOME 16Q; CHROMOSOME 4Q; EDITORIAL; GENE MUTATION; GENETIC RISK; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HOLTER MONITORING; LUNG VEIN; PRIORITY JOURNAL; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE;

ATRIAL FIBRILLATION; CATHETER ABLATION; HUMANS; MUTATION; RECURRENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 76449091302     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.12.009     Document Type: Editorial

References (36)

1. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339 (1998) 659-666
2. Gudbjartsson D.F., Holm H., Gretarsdottir S., et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet 41 (2009) 876-878
3. Benjamin E.J., Rice K.M., Arking D.E., et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet 41 (2009) 879-881
4. Gudbjartsson D.F., Arnar D.O., Helgadottir A., et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448 (2007) 353-357
5. Kaab S., Darbar D., van Noord C., et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J 30 (2009) 813-819
6. Miyasaka Y., Barnes M.E., Gersh B.J., et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114 (2006) 119-125
7. Terasawa T., Balk E.M., Chung M., et al. Systematic review: comparative effectiveness of radiofrequency catheter ablation for atrial fibrillation. Ann Intern Med 151 (2009) 191-202
8. Jais P., Cauchemez B., Macle L., et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 118 (2008) 2498-2505
9. Krittayaphong R., Raungrattanaamporn O., Bhuripanyo K., et al. A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. J Med Assoc Thai 86 Suppl 1 (2003) S8-S16
10. Oral H., Pappone C., Chugh A., et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 354 (2006) 934-941
11. Pappone C., Augello G., Sala S., et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF study. J Am Coll Cardiol 48 (2006) 2340-2347
12. Stabile G., Bertaglia E., Senatore G., et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 27 (2006) 216-221
13. Wazni O.M., Marrouche N.F., Martin D.O., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293 (2005) 2634-2640
14. Pappone C., Rosanio S., Augello G., et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 42 (2003) 185-197
15. Rossillo A., Bonso A., Themistoclakis S., et al. Role of anticoagulation therapy after pulmonary vein antrum isolation for atrial fibrillation treatment. J Cardiovasc Med 9 (2008) 51-55
16. Calkins H., Brugada J., Packer D.L., et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Heart Rhythm 4 (2007) 816-861
17. Nademanee K., Schwab M.C., Kosar E.M., et al. Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol 51 (2008) 843-849
18. Themistoclakis S., Schweikert R.A., Saliba W.I., et al. Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm 5 (2008) 679-685
19. Letsas K.P., Weber R., Burkle G., et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace 11 (2009) 158-163
20. Mainigi S.K., Sauer W.H., Cooper J.M., et al. Incidence and predictors of very late recurrence of atrial fibrillation after ablation. J Cardiovasc Electrophysiol 18 (2007) 69-74
21. Shin D.I., Deneke T., Gorr E., et al. Predicting successful pulmonary vein isolation in patients with atrial fibrillation by brain natriuretic peptide plasma levels. Indian Pacing Electrophysiol J 9 (2009) 241-246
22. Amasyali B., Kose S., Aytemir K., et al. P wave dispersion predicts recurrence of paroxysmal atrial fibrillation in patients with atrioventricular nodal reentrant tachycardia treated with radiofrequency catheter ablation. Ann Noninvasive Electrocardiol 11 (2006) 263-270
23. Jiang H., Lu Z., Lei H., Zhao D., Yang B., and Huang C. Predictors of early recurrence and delayed cure after segmental pulmonary vein isolation for paroxysmal atrial fibrillation without structural heart disease. J Interv Card Electrophysiol 15 (2006) 157-163
24. Patel M.S., Srinivasan M., and Aalinkeel R. Metabolic programming by nutrition during early development. Indian J Exp Biol 38 (2000) 849-855
25. Park J.H., Oh Y.S., Kim J.H., et al. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on patients following ablation of atrial fibrillation. Korean Circ J 39 (2009) 185-189
26. Bertaglia E., Stabile G., Senatore G., et al. Predictive value of early atrial tachyarrhythmias recurrence after circumferential anatomical pulmonary vein ablation. Pacing Clin Electrophysiol 28 (2005) 366-371
27. Husser D., Adams V., Piorkowski C., Hindricks G., and Bollmann A. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 55 (2010) 747-753
28. Oral H., Knight B.P., Ozaydin M., et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol 40 (2002) 100-104
29. Young N.S., Ioannidis J.P., and Al-Ubaydli O. Why current publication practices may distort science. PLoS Med 5 (2008) e201
30. Ellinor P.T., Yi B.A., and MacRae C.A. Genetics of atrial fibrillation. Med Clin North Am 92 (2008) 41-51
31. Viviani Anselmi C., Novelli V., Roncarati R., et al. Association of rs2200733 at 4q25 with atrial flutter/fibrillation diseases in an Italian population. Heart 94 (2008) 1394-1396
32. Pencina M.J., D'Agostino Sr. R.B., D'Agostino Jr. R.B., and Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008) 157-172 207-12
33. Pencina M.J., and D'Agostino R.B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23 (2004) 2109-2123
34. Hlatky M.A., Greenland P., Arnett D.K., et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119 (2009) 2408-2416
35. Schnabel R.B., Sullivan L.M., Levy D., et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 373 (2009) 739-745
36. Mommersteeg M.T., Brown N.A., Prall O.W., et al. Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium. Circ Res 101 (2007) 902-909